REG - Trellus Health PLC - Change of Registered Office

Trellus HealthAnnouncement

27/12/2024 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241227:nRSa4524Ra&default-theme=true

RNS Number : 4524R  Trellus Health PLC  27 December 2024

 

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Change of Registered Office

 

LONDON, U.K. AND NEW YORK, U.S. (27 December 2024). Trellus Health plc (AIM:
TRLS), a healthcare company offering a digital platform and services designed
to deliver scientifically validated, personalised programs and integrated
value-based healthcare and pharma solutions for the management of complex
chronic conditions, announces today that its registered office address,
previously situated at Avon House, 19 Stanwell Road, Penarth, Cardiff, United
Kingdom, CF64 2EZ, has changed with immediate effect to 201 Temple Chambers, 3
- 7 Temple Avenue, London, England, EC4Y 0DT.

 

For further information please contact:

 

 Trellus Health plc                                                 https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder         Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)              Tel: +44 (0)20 7496 3000
 Jen Boorer / James Todd / Jalini Kalaravy

 Walbrook PR                        Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                    (mailto:trellus@walbrookpr.com)
 Paul McManus / Phillip Marriage /  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 /

 Louis Ashe-Jepson                  +44 (0)7747 515 393

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate™ resulted in over 90%
fewer hospitalisations and a reduction of over 70% in emergency room visits.
Given the common emotional and mental health struggles associated with a
variety of chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.

 

Trellus Health(®) also offers a seamless solution for pharmaceutical
partners from clinical trials to commercialisation, harnessing
resilience-based methods to drive both trial and patient support success by
empowering patients to stay engaged, adhere to their treatment, and manage
their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROBDLFLZLLFFBB